Repeat Influenza Vaccination Yields Reduced Antibody ResponseHCWs who were vaccinated fewer times.1
The investigators enrolled 182 full time HCWs from the Peter MacCallum Cancer Centre in Melbourne, Victoria, who had not yet been vaccinated for the 2015 influenza season in the study. The majority (n=149, 82%) reported a history of multiple previous vaccinations and were designated the “high” vaccine group, compared with 33 individuals (18%) in the “low” vaccine group. “People were dichotomised to low and high, where low included people vaccinated once or twice before,” explained study coauthor Sheena Sullivan, PhD, in an email to Infectious Disease Advisor.
The high vaccine group averaged 4.8 (standard deviation (SD) 0.4) vaccinations over the previous five years compared with 2.2 (SD 0.9) in the low vaccine group. Mean age in the high vaccine group was higher compared with the low vaccination group (44 vs 33 years, respectively; P <.001), and they had been employed longer (seven vs two years, respectively; P <.001).
Prior to vaccination, both the high and low vaccination groups had similar levels of geometric mean titers (GMTs) for all 3 viral strains in the trivalent vaccine (A/California/7/2009 [H1N1], A/Switzerland/9715293/2013 [H3N2], and B/Phuket/3073/2013 [B Yamagata lineage]). The vaccine increased antibody titers for all strains in both groups with greatest gains observed in 2 strains of the low vaccination group for influenza (A/California/7/2009 [P =.02] and A/South Australia/55/2014 [P =.04]). At the end of the season, GMT titers for the A/California/7/2009 strain declined significantly for both groups (P <.001) while GMT titers for the A/South Australia/55/2014 strain were maintained. Another 25 HCWs (21 in the high vaccine group and four in the low vaccine group) who demonstrated a four-fold increase in titers postseason (largely to the Australian and Phuket strains) were excluded from analysis.
Vaccine effectiveness (VE) to A/H3N2 virus over five years in the United States was shown in an earlier study2 to be highest among individuals who had not been previously vaccinated (VE 65%, 95% CI: 36%-80%) compared with those who had received four to five vaccines over the period (VE 24%, 95% CI: 3%-41%).
“This was a study of immunogenicity, not vaccine effectiveness,” Dr. Sullivan pointed out, noting that “Immunogenicity is only a proxy of protection. Immunogenicity was assessed against the vaccine strains, which does not necessarily provide us information about the protection afforded against circulating influenza strains.” The decline in antibody response to the A/California/7/2009 strain may have been associated with lessened opportunity for boosting due to circulating strains that season, the authors observed.
The results of this study indicate a trend toward decreased serologic response to vaccines among HCWs who were highly vaccinated compared with those who had fewer vaccines, although the investigators contend that current guidelines for annual vaccination should not yet be changed. “I would not make any recommendation for changing a policy on the basis of just one study,” Dr. Sullivan wrote. “Further research is needed to confirm or refute our findings before considering policy changes.”
Note: This article was reprinted with permission. It was originally published at Infectious Disease Advisor.